Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.
Standard
Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. / Escherich, Gabriele; Richards, S; Stork, L C; Vora, A J.
In: LEUKEMIA, Vol. 25, No. 6, 6, 2011, p. 953-959.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.
AU - Escherich, Gabriele
AU - Richards, S
AU - Stork, L C
AU - Vora, A J
PY - 2011
Y1 - 2011
N2 - Mercaptopurine has been used in continuing treatment of childhood acute lymphoblastic leukaemia since the mid 1950s. Recent advances in the understanding of thiopurine pharmacology indicated that thioguanine (TG) might be more effective than mercaptopurine (MP). The US and UK cooperative groups began randomised thiopurine trials and agreed prospectively to a meta-analysis. All randomised trials of TG versus MP were sought, and data on individual patients were analysed by standard methods. Combining three trials (from US, UK and Germany), the overall event-free survival (EFS) was not significantly improved with TG (odds ratio (OR)=0.89; 95% confidence interval 0.78-1.03). Apparent differences in results between trials may be partly explained by the different types of patients studied. The larger treatment effect reported in males in the US trial was confirmed in the other trials. There was heterogeneity between sex/age subgroups (P=0.001), with significant EFS benefit of TG only observed for males aged
AB - Mercaptopurine has been used in continuing treatment of childhood acute lymphoblastic leukaemia since the mid 1950s. Recent advances in the understanding of thiopurine pharmacology indicated that thioguanine (TG) might be more effective than mercaptopurine (MP). The US and UK cooperative groups began randomised thiopurine trials and agreed prospectively to a meta-analysis. All randomised trials of TG versus MP were sought, and data on individual patients were analysed by standard methods. Combining three trials (from US, UK and Germany), the overall event-free survival (EFS) was not significantly improved with TG (odds ratio (OR)=0.89; 95% confidence interval 0.78-1.03). Apparent differences in results between trials may be partly explained by the different types of patients studied. The larger treatment effect reported in males in the US trial was confirmed in the other trials. There was heterogeneity between sex/age subgroups (P=0.001), with significant EFS benefit of TG only observed for males aged
M3 - SCORING: Journal article
VL - 25
SP - 953
EP - 959
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 6
M1 - 6
ER -
